.ANALYSIS HIGHLIGHT.16 Oct 2024.
In the NIAGARA trial, the addition of perioperative durvalumab to standard therapy for muscle-invasive sac cancer strengthened event-free as well as on the whole survival, noting a new treatment choice for this problem.